CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

How Kyverna rode CAR T’s autoimmune wave to the FDA’s door

NDA FilingPositive
AI Analysis

Summary

Kyverna Therapeutics is positioned to become the first company to file a CAR-T cell therapy for autoimmune disease with the FDA, developing a pipeline-in-a-product approach to transform treatment paradigms in this indication.

Importance:7/10
Sentiment:
0.70
CAR-Tcell therapyautoimmune diseaseregulatory filingFDA
Related Companies

Read the original article

Published by BioSpace on July 20, 2026 4:14 AM

Read Original